Upgrade to SI Premium - Free Trial

Alnylam Pharma (ALNY)

303.27 -0.37 (0.12%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/30/26)

Latest Headlines

H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) June 5, 2026 8:17 AM - StreetInsider Alnylam partners with Inceptive in $2B AI collaboration for drug discovery June 3, 2026 4:45 PM - StreetInsider Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics June 3, 2026 4:45 PM - BizWire Form 4 ALNYLAM PHARMACEUTICALS, For: Jun 01 Filed by: PYOTT DAVID E I June 3, 2026 4:25 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: Jun 01 Filed by: Cravatt Benjamin June 3, 2026 4:24 PM - SEC Filing Form 3 ALNYLAM PHARMACEUTICALS, For: Jun 01 Filed by: Cravatt Benjamin June 3, 2026 4:21 PM - SEC Filing Form 144 ALNYLAM PHARMACEUTICALS, Filed by: PYOTT DAVID E I June 1, 2026 4:25 PM - SEC Filing JPMorgan says large-cap biotech is back as profits and pipelines fuel upside May 28, 2026 4:07 PM - StreetInsider Form 8-K ALNYLAM PHARMACEUTICALS, For: May 20 May 27, 2026 4:31 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: Sigal Charles Elliott May 22, 2026 4:21 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: SCHULMAN AMY W May 22, 2026 4:19 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: Reitan Colleen F May 22, 2026 4:17 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: PYOTT DAVID E I May 22, 2026 4:15 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: KELLOGG PETER N May 22, 2026 4:13 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: HAMBURG MARGARET A May 22, 2026 4:11 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: BRANDICOURT OLIVIER May 22, 2026 4:09 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: Ausiello Dennis A May 22, 2026 4:07 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: Arbuckle Stuart A May 22, 2026 4:05 PM - SEC Filing JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms May 20, 2026 3:10 PM - StreetInsider JPMorgan Reinstates Alnylam Pharmaceuticals (ALNY) at Overweight May 20, 2026 4:30 AM - StreetInsider Alnylam Issues 2025 Corporate Responsibility Report May 19, 2026 8:30 AM - BizWire Citi Starts Alnylam Pharmaceuticals (ALNY) at Buy May 18, 2026 4:14 PM - StreetInsider Form 4 ALNYLAM PHARMACEUTICALS, For: May 13 Filed by: SCHULMAN AMY W May 14, 2026 4:18 PM - SEC Filing Form SCHEDULE 13G/A ALNYLAM PHARMACEUTICALS, Filed by: Capital World Investors May 14, 2026 1:56 PM - SEC Filing Form SCHEDULE 13G/A ALNYLAM PHARMACEUTICALS, Filed by: Capital Research Global Investors May 14, 2026 10:20 AM - SEC Filing Alnylam presents vutrisiran data showing benefits across ATTR-CM patients May 12, 2026 5:27 AM - StreetInsider New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patien May 12, 2026 2:30 AM - BizWire Alnylam to Webcast Presentations at Upcoming Investor Conferences May 7, 2026 8:00 AM - BizWire Form SCHEDULE 13G/A ALNYLAM PHARMACEUTICALS, Filed by: FMR LLC May 6, 2026 11:01 AM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) May 5, 2026 7:29 AM - StreetInsider Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM May 4, 2026 8:30 AM - BizWire Alnylam Pharmaceuticals (ALNY) PT Lowered to $447 at Bernstein SocGen Group May 1, 2026 9:52 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Raised to $370 at Morgan Stanley May 1, 2026 9:13 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Raised to $377 at Wells Fargo May 1, 2026 7:53 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Lowered to $445 at RBC Capital May 1, 2026 6:36 AM - StreetInsider Form 10-Q ALNYLAM PHARMACEUTICALS, For: Mar 31 April 30, 2026 8:21 AM - SEC Filing Form 8-K ALNYLAM PHARMACEUTICALS, For: Apr 30 April 30, 2026 8:08 AM - SEC Filing Alnylam Pharma (ALNY) Tops Q1 EPS by 108c, provides guidance April 30, 2026 8:02 AM - StreetInsider Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress April 30, 2026 8:00 AM - BizWire Form SCHEDULE 13G ALNYLAM PHARMACEUTICALS, Filed by: VANGUARD CAPITAL MANAGEMENT LLC April 29, 2026 4:45 PM - SEC Filing U.S. Biotech stocks: Q1 earnings previews April 26, 2026 8:00 PM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Lowered to $448 at Bernstein SocGen April 24, 2026 8:34 AM - StreetInsider When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech April 20, 2026 8:30 AM - Globe NewsWire Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results April 16, 2026 8:00 AM - BizWire Alnylam Pharmaceuticals (ALNY) PT Lowered to $505 at Truist Securities April 13, 2026 7:09 AM - StreetInsider Form 4 ALNYLAM PHARMACEUTICALS, For: Apr 02 Filed by: McLaughlin Melissa April 7, 2026 4:21 PM - SEC Filing Form 3 ALNYLAM PHARMACEUTICALS, For: Mar 25 Filed by: McLaughlin Melissa April 7, 2026 4:17 PM - SEC Filing Form ARS ALNYLAM PHARMACEUTICALS, For: Dec 31 April 6, 2026 5:02 PM - SEC Filing Form DEFA14A ALNYLAM PHARMACEUTICALS, April 6, 2026 4:32 PM - SEC Filing Form DEF 14A ALNYLAM PHARMACEUTICALS, For: May 20 April 6, 2026 4:31 PM - SEC Filing Form 144 ALNYLAM PHARMACEUTICALS, Filed by: McLaughlin Melissa April 6, 2026 4:06 PM - SEC Filing Alnylam presents cardiovascular drug data at medical conference March 30, 2026 1:00 PM - StreetInsider New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management March 30, 2026 1:00 PM - BizWire Form SCHEDULE 13G/A ALNYLAM PHARMACEUTICALS, Filed by: VANGUARD GROUP INC March 26, 2026 3:25 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) March 26, 2026 6:40 AM - StreetInsider Stifel on Alnylam Pharmaceuticals (ALNY): 'positively biased after the pullback' March 25, 2026 11:39 AM - StreetInsider BofA on Alnylam (ALNY): 'AI-enabled diagnostics will help increase diagnosis rates' March 24, 2026 3:10 PM - StreetInsider Morgan Stanley: 'we see Amvuttra as well positioned' March 24, 2026 3:08 PM - StreetInsider Alnylam partners with Viz.ai and American Heart Association on ATTR-CM care March 24, 2026 7:30 AM - StreetInsider Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association March 24, 2026 7:30 AM - BizWire Jefferies Downgrades Alnylam Pharmaceuticals (ALNY) to Hold March 16, 2026 12:54 AM - StreetInsider Alnylam to Webcast TTR Investor Webinar March 10, 2026 8:00 AM - BizWire Full Article List